Quality Standards & Botanical Research
Our botanical formulations are developed following quality standards and guided by published research into wellness support
EPI1's scientific approach is built on decades of research into immunology, the endocannabinoid system, and nutritional therapeutics
Our research methodology combines traditional clinical science with cutting-edge AI analytics through AI powered Clinical Research. This integration allows us to:
EPI1 employs multi-tiered validation to ensure safety, efficacy, and reproducibility:
Our research focuses on conditions with significant unmet medical needs and shared immunological mechanisms
Cytokine dysregulation and persistent inflammation (elevated IL-6, TNF-α, IFN-γ)
Mitochondrial dysfunction and cellular energy depletion
Endocannabinoid system modulation for neuro-immune balance
Microbiome restoration and gut-immune axis healing
Early Results: Patients report significant reduction in fatigue, brain fog, and inflammation markers within 4-8 weeks
Immune homeostasis restoration without suppression
T-regulatory cell enhancement and balance
Anti-inflammatory pathway activation (CB2, PPAR-γ)
Oxidative stress reduction and cellular protection
Conditions Studied: Rheumatoid arthritis, lupus, inflammatory bowel disease, psoriasis, multiple sclerosis
Chemotherapy-induced peripheral neuropathy (CIPN) management
Cancer-related fatigue and inflammation reduction
Quality of life improvements during treatment
Immune resilience and recovery enhancement
Adjunctive Approach: Designed to complement standard cancer treatments, not replace them
Stem cell therapy enhancement through immune modulation
Bioactive sutures for accelerated wound healing
Tissue regeneration and cellular repair mechanisms
Integration with AI-driven personalized protocols
Innovation: Combining cellular therapies with immunomodulation for synergistic healing
Feedback from customers using our botanical formulations as part of their wellness routine
* Results based on observational studies. Formal clinical trials in progress. Individual results may vary.
Collaborating with leading institutions to advance clinical validation and regulatory pathways
Universidad Ana G. Méndez
Puerto Rico Clinical & Translational Research Consortium
Research & Development Institute
EPI1 is actively pursuing funding through NIH translational research programs to support clinical validation and accelerate regulatory approval pathways.
Our research aligns with NIH priorities including Long COVID recovery, autoimmune disease management, and precision medicine approaches.
Planned studies and expansion of our clinical research program
2024-2025
Ongoing
2025-2026
2026+
Whether you're a patient interested in participating in clinical studies, a researcher seeking collaboration, or an institution looking for partnership opportunities — we welcome your inquiry.
All research conducted under IRB approval and FDA-aligned protocols. Patient safety and data privacy are our highest priorities.